Vida Diagnostics Receives Strategic Investment from UnityPoint Health Ventures
Summary
UnityPoint Health (UPH) and VIDA will partner to develop and commercialize VIDA’s AI-powered lung analysis solutions (LungPrintⓇ), designed to positively impact patient outcomes and quality of care, and lower overall health care costs. LungPrint is a fully automated AI-powered analysis of an inspiratory chest CT scan, providing a quick flag of lung density abnormalities that may be indicative of emphysema or interstitial lung disease. The solution addresses the large and growing burden of pulmonary disease in clinical care. The partnership provides access to UPH’s extensive multi-state network of hospitals and clinics, and to its network of clinical experts who will contribute insights to the company’s solution roadmap and commercialization processes. Wood, Ph.D., CEO, Vida also secured non-dilutive funds from the Iowa Economic Development Authority (IEDA).
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
